Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease（ASPIRE）：A Randomized Controlled, Double-blind Study

NCT06543563 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06543563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06543563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease（ASPIRE）：A Randomized Controlled, Double-blind Study
Lead sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
August 9, 2024
Completion date
January 31, 2026
Enrollment
102 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

deep brain stimulation, esketamine, pd - parkinson's disease